Can low thyroid hormone activity raise homocysteine levels?

Thyroid hormones serve as critical regulators of systemic metabolism, and their deficiency significantly impairs the clearance of metabolic waste products and cardiovascular risk markers.

Clinical evidence

• Independent association: Hypothyroid patterns, including both overt and subclinical hypothyroidism (SCH), are consistently associated with elevated serum homocysteine. Large-scale multivariate models demonstrate that TSH remains a strong independent predictor of elevated homocysteine even after adjusting for folate, vitamin B12, age, and creatinine.
• Clinical metrics: Meta-analyses reveal that patients with SCH exhibit a significant pooled increase in fasting total homocysteine of approximately +1.16 µmol/L compared to euthyroid controls. This hyperhomocysteinemia is highly reversible, as restoring a euthyroid state with levothyroxine therapy successfully reduces homocysteine levels.

Mechanistic explanations

• Impaired cofactor synthesis: Low thyroid activity reduces the metabolic conversion of riboflavin into its active cofactor form, flavin adenine dinucleotide (FAD). This FAD deficiency destabilizes methylenetetrahydrofolate reductase (MTHFR)—a key flavoprotein—which decreases its hepatic activity and slows down the remethylation of homocysteine to methionine.
• Enzymatic downregulation: Thyroid hormone deficiency inhibits other key remethylation enzymes, including betaine-homocysteine methyltransferase (BHMT) and S-adenosylmethionine (SAM) synthase. Additionally, it downregulates the transsulfuration pathway by decreasing the activity of cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGL).
• Reduced renal clearance: Beyond localized hepatic enzyme impairment, low thyroid hormone activity reduces the glomerular filtration rate (GFR), which directly compromises the renal clearance of homocysteine and drives up circulating blood levels.

Bottom line

• Low thyroid activity independently slows homocysteine metabolism through dual-pathway enzymatic downregulation and reduced renal clearance, elevating this key cardiovascular risk marker even when vitamin B12 and folate levels are adequate.